Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 17/20 | 0.69 |
| ▸ | SLC6A3 known ✓ | Q01959 | 16/20 | 0.69 |
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.52 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.52 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.52 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.52 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.52 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8008081 | 0.99 | CYP3A4 (0.76) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| SCHEMBL4606333 | 0.98 | CYP3A4 (0.76) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| Hydrochloric Acid SCHEMBL2105 | 0.88 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| Hydrochloric Acid SCHEMBL10336934 | 0.87 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| SCHEMBL2379467 | 0.86 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| SCHEMBL682189 | 0.86 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| SCHEMBL2378403 | 0.86 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| Water SCHEMBL10423764 | 0.85 | CYP3A4 (0.94) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| Hydrochloric Acid SCHEMBL6476842 | 0.85 | SLC6A4 (0.71) | CYP3A4ALOX15TSHRTP53SLC6A4 | |
| SCHEMBL3517972 | 0.82 | SLC6A4 (1.00) | CYP3A4ALOX15TSHRTP53SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1169029-A4 | METHOD OF TREATING SLEEP APNOEA | ABBOTT GMBH & CO KG (DE) | 2004-01-21 | — | — | EP | claimed |
| JP-2002539254-A | — | — | 2002-11-19 | — | — | JP | claimed |
| WO-2002019998-A2 | A METHOD OF TREATING WEIGHT GAIN ASSOCIATED WITH ATYPICAL ANTIPSYCHOTIC USE | ELI LILLY AND COMPANY (US) | 2002-03-14 | — | — | WO | claimed |
| EP-1178790-A1 | TREATMENT TO LOWER PLATELET ADHESIVENESS | Knoll GmbH (DE) | 2002-02-13 | — | — | EP | claimed |
| EP-1169029-A1 | METHOD OF TREATING SLEEP APNOEA | Knoll GmbH (DE) | 2002-01-09 | — | — | EP | claimed |
| EP-1169028-A1 | TREATMENT OF HIATIAL HERNIA | Knoll GmbH (DE) | 2002-01-09 | — | — | EP | claimed |
| WO-2000056319-A1 | TREATMENT OF ORTHOSTATIC HYPOTENSION | KNOLL PHARMACEUTICAL COMPANY (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056150-A1 | TREATMENT OF PREMENSTRUAL SYNDROME | KNOLL PHARMACEUTICAL COMPANY (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056307-A1 | TREATMENT OF HIATIAL HERNIA | KNOLL GMBH (DE) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056149-A1 | METHOD OF TREATING ANXIETY DISORDERS | KNOLL PHARMACEUTICAL COMPANY (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056310-A1 | TREATMENT OF CHRONIC FATIGUE SYNDROME | KNOLL PHARMACEUTICAL COMPANY (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056151-A1 | METHOD OF TREATING OBSESSIVE-COMPULSIVE DISORDER | KNOLL PHARMACEUTICAL COMPANY (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056314-A1 | METHOD OF TREATING SLEEP APNOEA | KNOLL GMBH (DE) | 2000-09-28 | — | — | WO | claimed |
| EP-1007023-A1 | MEDICAL TREATMENT | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-06-14 | — | — | EP | claimed |
| EP-0973511-A1 | USE OF SIBUTRAMINE ANALOGUES TO LOWER LIPID LEVELS | Knoll AG (DE) | 2000-01-26 | — | — | EP | claimed |
| WO-1998013034-A1 | USE OF SIBUTRAMINE ANALOGUES TO LOWER LIPID LEVELS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-04-02 | — | — | WO | claimed |
| WO-1998013033-A1 | MEDICAL TREATMENT | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-04-02 | — | — | WO | claimed |
| EP-0397831-A1 | TREATMENT OF OBESITY. | BOOTS CO PLC (GB) | 1990-11-22 | — | — | EP | claimed |
| EP-0230742-B1 | N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it | The Boots Company PLC (GB) | 1990-09-26 | — | — | EP | claimed |
| WO-1990006110-A1 | TREATMENT OF OBESITY | THE BOOTS COMPANY PLC (GB) | 1990-06-14 | — | — | WO | claimed |